We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Supports Expanded EUAs for Pfizer-BioNTech and Moderna Pediatric COVID-19 Vaccines
FDA Supports Expanded EUAs for Pfizer-BioNTech and Moderna Pediatric COVID-19 Vaccines
In a briefing document issued ahead of a two-day meeting by its vaccines advisory committee that begins today, the FDA indicated its support for Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for children age six months through four years.